BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ADvantage Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ADvantage Therapeutics's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07107074-754@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AD04: Phase 2 readout est. (NCT07107074)
DESCRIPTION:AD04\, phase 2\, Alzheimer's Disease.\nStudy: Effects of a Wide
 ly Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double
 -blind Study to Assess the Safety and Efficacy of AD04 in Patients With Ea
 rly Alzheimer's Disease - ADVANCE\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ad04#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07107074
URL:https://assetmemo.bio/drug/ad04#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
